How Many People Die From the Flu Each Year in the US?

Influenza kills a widely varying number of Americans each season, and the honest answer is a range rather than a single number. One long-running analysis covering 1999 through 2018 put the mean at roughly 10,000 deaths per year from influenza-associated respiratory causes, but individual seasons swung from fewer than 400 deaths to more than 23,000.{¹} During the 1990s, statistical models that cast a wider net over cardiac and respiratory deaths attributed an average of about 36,000 deaths per season to the virus.{²} The gap between those figures is less about the flu changing and more about how you count, which turns out to be the central challenge of flu mortality surveillance.

Why the Death Toll Is Always an Estimate

Flu rarely shows up neatly on a death certificate. The virus is seldom isolated near the time of death, and many people who die of flu-related complications get coded under pneumonia, heart disease, or other acute conditions instead. During the 1990s, standard viral surveillance picked up only about 1,000 to 2,000 influenza deaths per season, while statistical models that accounted for the undercounting estimated 36,000.{²} That gap is staggering, and it exists because the flu sets off chain reactions in the body that end up being classified under whatever organ system ultimately fails.

An Australian record-linkage study illustrates the scale of the problem at the individual level. Among 40 people who had a lab-confirmed influenza notification and died within a few months of specimen collection, only a quarter had influenza listed as a certified cause of death. Circulatory illness was coded in a third of the cases, and other types of pneumonia and even cancers accounted for the rest.{³} Death certificate counts consistently produce much lower estimates of flu mortality than the excess-mortality models that public health agencies rely on.{⁴}

Because direct counts miss so many deaths, researchers use statistical models that compare deaths during flu season to a baseline of what would be expected if the virus were not circulating. Several different modeling approaches have been tested head-to-head, and most of them produce similar estimates that track closely with one another from season to season.{⁵} The models are not perfect, but they are the best tool available for a pathogen that hides behind the complications it causes.

Who Dies From the Flu

The burden falls overwhelmingly on older adults. Among underlying pneumonia-and-influenza deaths in the United States, roughly 90% of influenza-associated deaths occurred in people aged 65 and older. The same proportion held when researchers broadened the scope to include all respiratory and circulatory deaths linked to influenza.{⁶} The excess mortality rate for adults 65 and older was about 20.5 per 100,000, dwarfing the rate for any younger age group.{¹}

That does not mean younger people are safe. The 50-to-64 age group carries the second-highest mortality rate, and seasons dominated by certain virus strains can shift the age profile of who gets hit hardest. But in any given year, the single most important risk factor for dying of the flu is being over 65, often with underlying heart or lung disease that the virus exploits.

Children and Flu Deaths

Pediatric flu deaths are rarer in absolute numbers but draw outsized public attention, partly because they are tracked individually by the CDC rather than estimated through models. During the 2024-25 season, 280 pediatric flu deaths were reported in the United States, a rate of 3.8 per million children. The median age at death was 7, and the mortality rate was highest among infants younger than 6 months. More than half of the children who died had at least one underlying medical condition, most commonly a neurological condition. Among vaccine-eligible children with known vaccination status, 89% had not been fully vaccinated that season.{⁷}

A longer look at 2010 through 2016 found an average of about 675 pediatric flu deaths reported over that entire span, or roughly 100 per year. Half of those children had no preexisting medical conditions at all. Compared to children with underlying health problems, otherwise healthy children who died tended to be younger, less likely to have been vaccinated, and more likely to die before even reaching a hospital.{⁸} The speed of deterioration in previously healthy kids is one of the things that makes pediatric flu deaths so alarming to clinicians.

How the Flu Actually Kills

Most people picture the flu as a respiratory illness, and it is, but the virus kills through a surprisingly wide range of mechanisms. The most common fatal pathway is secondary bacterial pneumonia. After the flu damages the lining of the airways, bacteria that normally live harmlessly in the upper respiratory tract can invade the lungs. Autopsy data from the 1918 pandemic showed this pattern clearly: the vast majority of deaths resulted not from the influenza virus itself but from bacterial pneumonia caused by common bacteria like pneumococci and staphylococci.{⁹} That dynamic has not changed. Secondary bacterial pneumonia after viral respiratory infection remains a major driver of severe illness and death.{¹⁰}

The cardiovascular system is another major target. A meta-analysis found moderate-certainty evidence that influenza infection increases the risk of acute heart attack by more than fivefold.{¹¹} The infection promotes inflammation and blood clotting throughout the body, which can destabilize arterial plaques and trigger heart attacks in people with underlying atherosclerosis.{¹²} This is a big part of why so many flu deaths end up coded as cardiac events rather than respiratory infections.

In the most severe cases, influenza can trigger full-blown sepsis and acute respiratory distress syndrome, with or without a bacterial co-infection. In intensive care settings during winter, clinicians are advised to suspect influenza not only in patients with classic flu symptoms but also in those presenting with severe pneumonia, sepsis, and even inflammation of the heart or brain.{¹³}

Why Some Flu Seasons Are Far Deadlier Than Others

The enormous season-to-season swing in death tolls is not random. One of the biggest determinants is which strain of the virus dominates. Seasons driven by influenza A H3N2 tend to be deadlier than those driven by H1N1 or influenza B. A study comparing hospitalized patients in Taiwan found that those with seasonal H3N2 had significantly higher in-hospital mortality than those with the 2009 pandemic H1N1 strain, despite presenting with fewer classic flu symptoms like sore throat and muscle pain.{¹⁴} A broader population-level analysis confirmed this pattern, finding that the age-standardized risk of death given infection was roughly two and a half times higher for seasonal H3N2 than for pandemic H1N1.{¹⁵}

Another factor is how much the circulating virus has changed since the previous season. Influenza A H3N2 in particular evolves rapidly, and when the virus drifts far enough from what the population’s immune system recognizes, larger and more severe epidemics tend to follow. Researchers have found that measures of how much the virus’s surface proteins have changed correlate with bigger epidemic waves and higher transmission rates.{¹⁶} Vaccine mismatch compounds the problem. When the vaccine strain drifts out of alignment with the circulating virus, effectiveness drops, as happened conspicuously during the 1997-98 season.{¹⁷}

Climate plays a role too. Thirty years of county-level data from across the United States showed that low absolute humidity was a particularly strong predictor of flu mortality, even after controlling for temperature. When air contained less than about 6 grams of water vapor per kilogram, flu deaths climbed. The analysis suggested that seasonal differences in humidity alone could explain roughly half of the seasonal differences in U.S. flu mortality.{¹⁸}

Vaccination and Antiviral Treatment

Flu vaccination does not prevent every death, but it meaningfully shifts the odds. Among older adults, vaccination has been associated with about a 30% reduction in all-cause mortality during flu epidemics, after adjusting for both measurable and unmeasurable differences between vaccinated and unvaccinated people.{¹⁹} A separate study focused on the oldest old found that vaccinated individuals had lower mortality regardless of age bracket or number of underlying conditions.{²⁰}

For people who do get sick, antiviral drugs like oseltamivir (Tamiflu) can reduce the risk of death if given in time. A pooled analysis of over 8,000 older adults hospitalized with influenza found that oseltamivir recipients had about an 18% lower risk of dying within 30 days. The benefit was significant for influenza A but not for influenza B, and the drug remained effective even when started more than 48 hours after symptom onset.{²¹} Among critically ill ICU patients, early oseltamivir treatment was associated with lower mortality in H3N2 infections specifically, with survivors spending nearly two fewer days in the ICU.{²²}

Those strain-specific differences in treatment response are worth noting. The fact that oseltamivir’s mortality benefit shows up clearly for influenza A but not B, and for H3N2 but not always H1N1 in the sickest patients, reinforces how much the biology of the specific circulating strain matters for outcomes in any given season.

Racial and Economic Disparities

Flu deaths do not fall equally across the population. A decade of U.S. surveillance data from 2009 to 2019 found that after adjusting for age, Black Americans had the highest rates of influenza-associated hospitalization, followed by American Indian or Alaska Native people and Hispanic people. Similar trends held for ICU admission rates, with the greatest disparities appearing in younger age groups.{²³}

Neighborhood-level economic factors amplify the problem. An analysis of hospitalization rates found that people living in the lowest-income neighborhoods were hospitalized for flu at more than twice the rate of those in the wealthiest areas, and those disparities were even wider during pandemic years compared to typical seasons.{²⁴} These gaps likely reflect differences in access to healthcare, vaccination rates, prevalence of chronic conditions, and living and working conditions that increase exposure. The virus may be indiscriminate, but its consequences are not.

How Flu Deaths Compare to COVID-19 and RSV

Flu, COVID-19, and respiratory syncytial virus (RSV) all circulate during the same winter months, and comparing their toll helps put flu mortality in context. During the 2024-25 respiratory season, the CDC estimated that influenza caused between 50,000 and 100,000 hospitalizations and a still-to-be-finalized number of deaths. In that same period, COVID-19 was linked to an estimated 290,000 to 450,000 hospitalizations and 34,000 to 53,000 deaths, while RSV accounted for 190,000 to 350,000 hospitalizations and 10,000 to 23,000 deaths.{²⁵}

At the individual patient level, the gap between flu and COVID has narrowed considerably since the early pandemic years. During the 2023-24 season, the 30-day risk of hospitalization was essentially identical for COVID-19 and influenza, and the 30-day risk of death was similar as well. Over a longer six-month window, COVID still carried a modestly higher mortality risk.{²⁶} RSV, often dismissed as a childhood illness, actually kills a comparable number of older adults as the flu in some seasons and follows a more stable year-to-year pattern.{¹}

Historical Pandemics and the Long Trend

The 1918 pandemic is the event that looms over all flu mortality discussions, and for good reason: it remains a statistical outlier unlike anything seen before or since in the recorded history of influenza in the United States. What is less commonly appreciated is that the two subsequent pandemics, in 1957-58 and 1968-69, were not nearly as exceptional. Their death tolls overlapped substantially with severe non-pandemic seasons in both magnitude and timing.{²⁷} In other words, a bad regular flu season can rival a mild pandemic, which is part of why public health officials treat seasonal flu as a persistent rather than occasional threat.

The Economic Weight of Flu Deaths

Beyond the human cost, flu exerts a massive economic toll. An analysis of annual seasonal influenza in the United States estimated direct medical costs averaging about $10.4 billion per year and lost earnings from illness and premature death adding another $16.3 billion. When economists factored in statistical life values to capture the full societal cost, the total economic burden came to roughly $87 billion annually.{²⁸} Pandemic scenarios push the numbers much higher. One modeling exercise estimated that a pandemic influenza outbreak could reduce U.S. GDP by $25 billion without vaccination and $45 billion when accounting for behavioral changes like people staying home from work.{²⁹} These figures make the case for flu prevention not just as a medical priority but as an economic one, and they partly explain why even modest improvements in vaccine coverage or antiviral access can have outsized returns.

1
JAMA Network Open. Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018
2
PubMed Central. US flu mortality estimates are based on solid science
3
PLoS ONE. Inaccurate Ascertainment of Morbidity and Mortality due to Influenza in Administrative Databases: A Population-Based Record Linkage Study
4
The Journal of Infectious Diseases. The Use of Death Certificate Data to Characterize Mortality Associated With Respiratory Syncytial Virus, Unspecified Bronchiolitis, and Influenza in the United States, 1999–2018
5
PubMed Central. Estimates of US influenza-associated deaths made using four different methods
6
JAMA. Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
7
Morbidity and Mortality Weekly Report. Influenza-Associated Pediatric Deaths — United States, 2024–25 Influenza Season
8
Pediatrics. Influenza-Associated Pediatric Deaths in the United States, 2010–2016
9
PubMed Central. Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness
10
PubMed Central. Postviral Complications: Bacterial Pneumonia
11
Cardiovascular Research. Systematic review and meta-analysis of respiratory viral triggers for acute myocardial infarction and stroke
12
PubMed Central. Influenza and cardiovascular disease: is there a causal relationship?
13
PubMed Central. Influenza virus-related critical illness: pathophysiology and epidemiology
14
PubMed Central. Increased Mortality in Seasonal H3N2 Patients Compared with those with Pandemic 2009 H1N1 in Taiwan, 2009-2010
15
PubMed Central. Relative incidence and individual-level severity of seasonal influenza A H3N2 compared with 2009 pandemic H1N1
16
eLife. Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States
17
PubMed. Influenza vaccine: the challenge of antigenic drift
18
American Journal of Epidemiology. Absolute Humidity, Temperature, and Influenza Mortality: 30 Years of County-Level Evidence from the United States
19
European Respiratory Journal. Impact of influenza vaccination on mortality risk among the elderly
20
PubMed Central. Impact of Influenza Vaccination on Mortality in the Oldest Old: A Propensity Score-Matched Cohort Study
21
PubMed Central. Oseltamivir Reduces 30-Day Mortality in Older Adults With Influenza: A Pooled Analysis From the 2012-2019 Serious Outcomes Surveillance Network of the Canadian Immunization Research Network
22
Clinical Infectious Diseases. Effect of Early Oseltamivir Treatment on Mortality in Critically Ill Patients With Different Types of Influenza: A Multiseason Cohort Study
23
JAMA Network Open. Rates of Influenza-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death by Race and Ethnicity in the United States From 2009 to 2019
24
Open Forum Infectious Diseases. Neighborhood Disparities in Influenza and Influenza like Illness Hospitalization During Seasonal and Pandemic Influenza
25
MMWR. Morbidity and Mortality Weekly Report. Respiratory Virus Activity — United States, July 1, 2024–June 30, 2025
26
PubMed Central. Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus
27
PubMed Central. Trends in recorded influenza mortality: United States, 1900-2004
28
PubMed. The annual impact of seasonal influenza in the US: measuring disease burden and costs
29
PubMed. Total Economic Consequences of an Influenza Outbreak in the United States